. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2010 Sep 24;84(1-2):43–50. doi: 10.1016/j.plefa.2010.09.002

Table 1.

ALX-tg recipients have increased cardiac allograft survival

Donor Strain	Recipient Strain	Lipoxin A₄ Analog	Allograft Survival (d)	Mean +/− SE
FVB	BALB/c	−	8,8,9,9,9	8.6 +/− 0.3
FVB ALX-tg	BALB/c	−	9,9	9.0
FVB ALX-tg	BALB/c	+	8,9,10	9.0 +/− 0.6
BALB/c	FVB	−	7,9,9,10,10	9.0 +/− 0.6
BALB/c	FVB ALX-tg	−	10,10,11,11,11	10.6 +/− 0.3^*
BALB/c	FVB ALX-tg	+	11,12,12	11.7 +/− 0.3^*,^†

Heterotopic cardiac transplants were performed as described in Materials and Methods. Allograft survival was assessed as the number of days that a pulse could be palpated in the allograft. Mean survival time in days of allografts in each experimental group.

P<0.05 for FVB ALX-tg compared to FVB organ recipient and

^†

P<0.05 for comparison between ALX-tg with and without LXA₄ analog (ATLa).